CONTEXT AND OBJECTIVES: Package leaflets are necessary for safe use of medicines. The aims of the present study were: 1) to assess the compliance between the content of the package leaflets and the specifications of the pharmaceutical regulations; and 2) to identify potential safety issues for patients. DESIGN AND SETTING: Qualitative descriptive study, involving all the package leaflets of branded medicines from the three most consumed therapeutic groups in Portugal, analyzed in the Department of Pharmacoepidemiology, School of Pharmacy, University of Lisbon. METHODS: A checklist validated through an expert consensus process was used to gather the data. The content of each package leaflet in the sample was classified as compliant or non-compliant with compulsory regulatory issues (i.e. stated dosage and descriptions of adverse reactions) and optional regulatory issues (i.e. adverse reaction frequency, symptoms and procedures in cases of overdose). RESULTS: A total of 651 package leaflets were identified. Overall, the package leaflets were found to be compliant with the compulsory regulatory issues. However, the optional regulatory issues were only addressed in around half of the sample of package leaflets, which made it possible to identify some situations of potentially compromised drug safety. CONCLUSION: Ideally, the methodologies for package leaflet approval should be reviewed and optimized as a way of ensuring the inclusion of the minimum essential information for safe use of medicines.
INTRODUCTION
Package leaflets are fundamental for the safe and effective use of medicines. 1, 2 Amongst other issues, the European Medicines Agency is responsible for the publication of legal requisites regarding the content of the package leaflets of medicinal products for human use, such as their template, the Quality Review of Documents for Human Product Information. 2 According to the Quality Review of Documents for Human Product Information, all package leaflets must include an initial content list and be structured in six sections ( Table 1) . 2 All versions (1 to 9) of the Quality Review of Documents for Human Product Information template, 2 except the first two, have required the presence of the abovementioned content list. 3 The first version of the Quality Review of Documents for Human Product
Information was published by the European Medicines Agency in 1996; however, the United States Food and Drug Administration had already been recommending the use of package inserts for oral contraceptives, intrauterine contraceptives devices and estrogens since 1977. [2] [3] [4] Package leaflets met resistance and criticism in the past, because at that time their use was associated with problems in the physician-patient relationship and in the production and distribution of medicinal products. 4 Usability testing was pioneered in Australia in the early 1990s, with the objective of proving the readability and comprehensibility of package leaflets. 5 In order to ensure proper and safe use of medicines, the European Medicines Agency also developed specific regulations on usability testing for package leaflets. The first guideline of the European Medicines Agency on the readability of labels and package leaflets of medicinal products was approved in 1998
and reviewed in 2009. 6 According to this guideline, "user testing"
should consist of enrolling a group of patients with the objective of identifying comprehension issues in the content of the package leaflets; in the event that any readability problem is identified in this test, those holding marketing authorization must successively act upon the information included in the package leaflets until it is completely understood. [6] [7] [8] takes into account the adoption of both Directives. In accordance with this law, the package leaflets should contain the following essential elements:
1. Name of the medicine (including strength and pharmaceutical form).
2. Pharmacotherapeutic category.
3. Therapeutic indications.
Directions or instructions for use (dosage, administration
route, frequency).
5. Information on the safety of the medicine (contraindications, precautions and interactions).
6. Adverse reactions.
7. Expiration date of the medicine.
8. Qualitative composition (active substances and excipients).
9. Other relevant information, such as the duration of treatment (or temporal limits) and procedures to be adopted in cases of overdose or poisoning (e.g. emergency procedures and antidotes).
In accordance with this regulation, "other relevant information" (point 9) was classified as optional, so that the description in the content of the package leaflets would be dependent on the pharmacological characteristics of the medicinal products (e.g.
package leaflets for medicines with narrow therapeutic margins must contain a description of overdose symptoms and specific procedures in cases of overdose).
9-11
A brief bibliographic review, using current databases 20 The importance of investigating the readability of package leaflets has also been confirmed in other previous studies. 3, 8, 20 In addition, the use of verbal descriptors (e.g. common, rare, not known, etc.) instead of numerical descriptors (e.g. percentages, fractions, etc.) was preferred by patients for expressing the frequency of adverse reactions, with results that were more favorable than when absolute frequencies were used as an alternative to frequency ranges. [16] [17] [18] Comprehension issues regarding dosage and adverse reactions were also previously identified. 12, 13 In another study, it was found that less than 20% of the participants were able to identify the symptoms of a rare life-threatening adverse reaction in a package leaflet for an antidepressant. 1 Other issues, such as the length of the package leaflet and labeling characteristics (e.g. overdose risk due to inadequate labeling) were also considered relevant to the investigation on readability. 3, 8, 19, 20 Taking into consideration that the readability of package leaflets remains a controversial issue, 8, 21 that there is a lack of published studies about regulatory inconsistencies in Portuguese package leaflets and that these issues have only been evaluated by marketing authorization holders and the National Medicines Agency (i.e. not by other external institutions such as universities), the relevance of the present study became clear.
OBJECTIVES
The aims of this study were: 1) to assess the compliance between the content of the package leaflets and pharmaceutical regulations, comprising compulsory issues, such as descriptions of dosages and adverse reactions and optional issues, such as duration of the treatment, frequency of administration and overdose symptoms; 2) to identify potential safety issues for patients; and 3) to evaluate possible qualitative inconsistencies within the sample of package leaflets and with package leaflets from other countries.
METHODS
The package leaflets in the sample were from medicines in the three most consumed therapeutic groups within the Portuguese The package leaflets not included were the following: overdose symptoms and procedures in cases of overdose). To this end, the descriptions of these issues in the content of the package leaflets were confirmed through application of a verification list or checklist ( Table 2) , thus making it possible to gather data for further analysis. The abovementioned compulsory and optional issues were specifically selected because, according to the literature, these issues are have the most influence on patients' comprehension. [12] [13] [14] [15] [16] [17] [18] Three experts (two regulatory affairs experts and one epidemiologist) validated the checklist through a consensus technique (individual interviews plus mini-Delphi), taking into consideration the relevance of each of the variables in the checklist ( Table 2) . Table 2 . Checklist used to gather the characteristics of the package leaflets The results from applying the checklist were organized in an Excel file. All the data were subjected to a quality control procedure in accordance with the requisites of the NBR 5425 standard. 25 Subsequently, package leaflets that were non-compliant (in relation to the compulsory or optional regulatory issues)
were ecologically compared with equivalent Portuguese package leaflets (or package leaflets from medicines with the same active substance, pharmaceutical form and dose) and with at least one equivalent package leaflet from other countries (package leaflets selected from public databases of medicines relating to the United Kingdom, United States of America and Australia).
Furthermore, the similarity between the sentences in section 3
("How to <take><use> X") of each package leaflet in the sample and the sentences described in section 3 of the Quality Review of
Documents for Human Product Information version 8 (European
Medicines Agency template) was also assessed. The chi-square test was used to identify statistically significant associations (at a significant level of P < 0.05) between package leaflets from the different therapeutic groups and/or countries, taking into consideration their compliance with regulatory issues.
RESULTS
As a consequence of applying the exclusion criteria ( The results from applying the checklist can be seen in Table 4 .
Only 218 package leaflets (33.5% of 651) described the duration of the treatment, of which 123 were in Group 2, 35 in Group 3 and 60 in More importantly, dosage (dose and/or schedule) was omitted from 14 package leaflets ( n = number of package leaflets; G = group (taking into consideration the number of package leaflets in each therapeutic group); G2 = Group 2 of the Portuguese prescribing guide, relating to the central nervous system; G3 = Group 3, relating to the cardiovascular system; G9 = Group 9, musculoskeletal system; SD = standard deviation. *Package leaflets presenting sentences in accordance with what is described in points 1.4.1; 1.4.2 and 1.4.3 of the checklist ( Table 2) ; † package leaflets of medicines free from adverse reactions; ‡ for example, induce vomiting or drink water. Note: the sum of frequencies from points 3.2, 3.3 and 3.4 do not fully correspond to 100%, since for some medicines the occurrence of overdose was not considered applicable, such as in the case of some topical forms. Relative to each of the 14 package leaflets without dose description ( Table 5) Table 5) .
In a subsample of the package leaflets (87 from non-steroidal anti-inflammatory drugs, 33 from angiotensin-convertingenzyme inhibitors and 27 from anxiolytics/sedatives/hypnotics), overdose symptoms were not described in respectively 36.8%, 24.2% and 11.1%.
DISCUSSION
In the European Union, medicines authorities are responsible for approving and updating the contents of package leaflets (e.g. in the event of urgent safety measures being required). 3, 26, 27 The scientific committees of the European Medicines Agency have developed and implemented diverse regulatory requirements in relation to medicinal products, such that manufacturers and marketing authorization holders have to observe these laws. 2 The lack of scientific publications about package leaflets confirms that there is a need for further independent specific studies in this area. Moreover, evaluations of package leaflets performed outside the legal systems (e.g. in academic centers) seem to be scarce, despite the fact that they are clearly advisable for safety reasons.
In the present study, the checklist was considered to be a useful and workable screening tool for assessing compliance between the content of the package leaflets and some relevant regulatory issues. It covered critical issues regarding adequate use of the medicines 28 
Mixed package leaflets
Naturally, patients consider that using package leaflets with more than one pharmaceutical form and/or strength is more difficult than using simple package leaflets (with only one pharmaceutical form and/or strength), because simple package leaflets present a lower degree of uncertainty regarding instructions on how to use the medicines. 30 The possible high complexity associated with interpretation of mixed package leaflets means that it is advisable to increase the accuracy of the "end-user testing" (e.g. increasing the number of questions about dosage in face-toface interviews). 30, 31 Even though the regulations of the European Medicines Agency recommend special care in approving mixed package leaflets, 30 approximately one third of our sample were classified as mixed package leaflets. This situation might be explained by the fact that the production costs of the mixed package leaflets imply lower costs than those associated with the simple package leaflets. However, post-commercialization data specifically about safe use of mixed package leaflets are unavailable.
Information on dosage (dose and frequency)
Omission of this essential information from package leaflets is considered controversial, because although package leaflets are one of the most accessible and reliable sources of drug information, some patients still prefer direct counseling from healthcare professionals. 13 Nevertheless, it was possible to identify in this sample that there were some package leaflets without descriptions of the dose and frequency of administration, which are compulsory regulatory issues. [9] [10] [11] Omission of dosage description might be considered acceptable in some cases, for example: 1) in the case of medicines for which administration is dependent on a healthcare professional's intervention (e.g. injectable forms); or 2) in the case of complex and adjustable administration regimens, such as those commonly used for treating well-known chronic diseases, e.g. fosinopril 20 mg tablets and ramipril + hydrochlorothiazide 2.5 mg/12.5 mg or 5 mg/25 mg tablets for hypertension, because in these cases, the chronic patients (if trained) are capable of making the necessary adjustments to their own dosage, according to their blood pressure.
The qualitative analysis on the content of package leaflets of equivalent medicines commercialized in other countries also showed cases of both complete and incomplete information about the dosage. However, there were differences and some of these may be explained by the slight variances between the regulatory requirements of these countries (i.e. United States, United
Kingdom and Australia). Hence, broader investigations on this issue are recommended.
Information on adverse reactions
Since the publication of the first Quality Review of Documents According to specialized publications, in the event of omission of data on the frequency of adverse reactions, patients might overestimate the risk and not adhere to treatment. 8, 12, 16 Despite the cultural and literacy differences between the populations of different countries, the impact of information on the adverse reactions described in package leaflets has never been specifically evaluated in Portugal. Following the trends of other European countries, 2, 20 almost all of the package leaflets in the sample included a description of adverse reactions (a compulsory regulatory issue) and more or less half of the package leaflets in the sample described the frequency of adverse reactions (an optional regulatory issue). 2, 10, 11 The omission of psychomotor limitations in some package leaflets of anxiolytic/sedative/hypnotic drugs, and also hypotension, dizziness and kidney and liver toxicity in some leaflets of angiotensin-converting-enzyme inhibitors might be considered to be an issue. These situations may possibly interfere with daily activities (e.g. driving) or pose other safety issues for patients with liver or kidney impairment. 24 The lack of consistency between the contents of package leaflets of equivalent medicines can be considered to be troublesome, given the possible interchangeability of prescriptions between brands of medicine with the growth in market share of generic drugs. 22 This might be explained by: 1) the existence of optional regulatory topics, thus allowing marketing authorization holders to decide whether to include certain types of information or not (i.e. optional regulatory issues); and 2) the fact that marketing authorization holders might deliberately not always provide complete information, for reasons such as the belief that the information is too intimidating, 1 with the capability of influencing patients' behavior, and consequently their health outcomes.
Information on overdoses
The characteristics of overdose episodes vary from patient to patient, for instance with regard to: 1) the pharmacological properties of the drugs (e.g. narrow therapeutic margins may produce different negative events with slight differences in the doses); or 2) the pharmaceutical forms of the medicines (e.g. parenteral medicines because of their usual high and fast bioavailability). 24 Updated content for package leaflets with regard to overdoses is considered necessary, since specific descriptions of signs and what to do in cases of overdose were not available in many of the package leaflets of the sample; however, the recommendation to consult a physician or pharmacist was present in the majority of the package leaflets. In contrast, it was possible to identify package leaflets of medicines with a low likelihood of intoxication (e.g. pyritinol)
that specifically described the symptoms and procedures in cases of an overdose. Regarding the descriptions of overdose symptoms and the specific procedures in cases of overdose described in the package leaflets, 2 the smallest number of omissions was found in the package leaflets of the medicines in Group 2 (central nervous system), probably because of their pharmacological properties and the high risk associated with use of medicines from this group (e.g. benzodiazepines). 24 With regard to appropriate actions in cases of overdose, this information was also sometimes omitted from the content of the package leaflets in other countries (e.g. it was found in only 75.3% of 271 German package leaflets).
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Information on the type of sentences
The updated nature and adequacy of the package leaflets in our sample was confirmed, given that all of them included at least sentence that was equal or similar (i.e. conveying an equivalent meaning) to those described in Table 2 . This observation was based on the facts that all the sentences described in avoiding the differences within the obligatory or optional regulatory information that were detected in the present study.
Overall, regulations regarding the readability of package leaflets should be updated with the objectives of standardizing the content of package leaflets and suppressing inconsistencies between the package leaflets of equivalent medicines.
CONCLUSIONS
While the majority of the package leaflets of a representative sample of Portuguese medicines were developed in conformity with compulsory regulatory issues, a small proportion of these leaflets needed to be updated with regard to missing information within their content (e.g. descriptions of doses, schedules and adverse reactions) and variability in the information amongst equivalent package leaflets. The relevance of this updating is even greater considering that the missing information is often not covered during visits to physicians or pharmacists (e.g. descriptions of overdose symptoms or overdose management). Thus, the incomplete content of some of the package leaflets might increase the risk of unsafe use of the medicines by the patients. The problems identified in this sample of Portuguese package leaflets probably also exist in the package leaflets of other European countries, since some of them were direct translations from the original country producer leaflets.
Ideally, the methodologies for package leaflet approval should be optimized as a way of ensuring the inclusion of essential information for safe use of medicines, not only through application of guidelines but also by using experimental methodologies and algorithms, which in our case would involve specifically enrolling Portuguese patients. Furthermore, future research and market monitoring regarding the use of package leaflets are advisable, e.g. creating specific forms for health professionals or patients to communicate problems associated with use of package leaflets.
